Brainstem

An awkward family reunion: Sea monsters are our cousins

Retrieved on: 
Wednesday, February 21, 2024

KANSAS CITY, Mo., Feb. 21, 2024 /PRNewswire/ -- The sea lamprey, a 500-million-year-old animal with a sharp-toothed suction cup for a mouth, is the thing of nightmares. A new study from the Stowers Institute for Medical Research discovered that the hindbrain—the part of the brain controlling vital functions like blood pressure and heart rate—of both sea lampreys and humans is built using an extraordinarily similar molecular and genetic toolkit.

Key Points: 
  • The team unexpectedly uncovered that a crucial molecular cue is very broadly required during vertebrate hindbrain development.
  • Because most vertebrates, including humans, have jaws, this striking difference in sea lampreys makes them valuable models for understanding the evolution of vertebrate traits.
  • Surprisingly, they found that the sea lamprey core hindbrain circuit is also initiated by retinoic acid, providing evidence that these sea monsters and humans are much more closely related than anticipated.
  • "People thought that because sea lampreys lack a jaw, their hindbrain was not formed like other vertebrates," said Krumlauf.

ZAP-X Gyroscopic Radiosurgery Platform Set to Revolutionize Neurosurgery at N. Copernicus Hospital in Gdansk

Retrieved on: 
Tuesday, February 6, 2024

In a groundbreaking development for brain tumor care in Poland, the Neurosurgery Centre at N. Copernicus Hospital in Gdansk is thrilled to announce the imminent installation of the ZAP-X® Gyroscopic Radiosurgery® platform.

Key Points: 
  • In a groundbreaking development for brain tumor care in Poland, the Neurosurgery Centre at N. Copernicus Hospital in Gdansk is thrilled to announce the imminent installation of the ZAP-X® Gyroscopic Radiosurgery® platform.
  • Completed in five or less brief outpatient visits, patients often resume their normal activities on the same day as treatment.
  • Historically, N. Copernicus Hospital lacked stereotactic radiosurgery capabilities, forcing patients to travel to other centers, often requiring substantial travel distances.
  • The Neurosurgery Centre at N. Copernicus Hospital looks forward to the positive impact the ZAP-X Gyroscopic Radiosurgery platform will have on advancing neurosurgical care and providing cutting-edge treatment options for patients in the region.

Westchester Medical Center to Debut ZAP-X Gyroscopic Radiosurgery System, Marking a Milestone for New York

Retrieved on: 
Tuesday, January 16, 2024

Westchester Medical Center, the flagship academic medical center for the Westchester Medical Center Health Network (WMCHealth), is set to become the first hospital in New York State to introduce the non-invasive surgical robotics platform, the ZAP-X® Gyroscopic Radiosurgery®, which will transform brain cancer treatments for patients throughout the Hudson Valley.

Key Points: 
  • Westchester Medical Center, the flagship academic medical center for the Westchester Medical Center Health Network (WMCHealth), is set to become the first hospital in New York State to introduce the non-invasive surgical robotics platform, the ZAP-X® Gyroscopic Radiosurgery®, which will transform brain cancer treatments for patients throughout the Hudson Valley.
  • Installation of the ZAP-X platform is expected to commence in mid-2024.
  • Typically completed in less than five brief outpatient visits, patients often resume their normal activities on the same day as the procedure.
  • This innovative method aims to improve patient outcomes by enhancing the ability to avoid critical structures like the brain stem, eyes, and optic nerves.

Overly flexible connective tissue causes problems in joints and throughout the body − and is often missed by doctors

Retrieved on: 
Friday, September 1, 2023

Connective tissue is found throughout the human body, within and between structures as varied as muscles, nerves and internal organs.

Key Points: 
  • Connective tissue is found throughout the human body, within and between structures as varied as muscles, nerves and internal organs.
  • Many people, especially young women, have very flexible connective tissue.
  • Hypermobile connective tissue can also cause serious health problems throughout the body, including the gut, nerves, skin, urinary tract and even immune system.

Wide range of symptoms

    • While some forms have genetic markers, more than 90% of hypermobility conditions – including hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder – do not.
    • Symptoms and severity can differ greatly from person to person and vary over time.
    • Symptoms can include widespread pain and frequent injury, irritable bowel syndrome, indigestion, hernias, frequent bruising and poor skin healing, trouble breathing, migraines and headaches, dizziness, fatigue, insomnia, anxiety and trouble concentrating.
    • Hypermobility experts now believe Ehlers-Danlos syndrome is not as rare as previously thought – and many people are misdiagnosed or undiagnosed.

Difficulties with diagnosis

    • Lack of a diagnosis can be frightening and discouraging for people with hypermobility spectrum disorder.
    • Patients are often told nothing is wrong with them and they are just complaining too much or have low pain tolerance.
    • A delayed diagnosis leads to worse function, increased pain and disability.

How physical therapy can help hypermobility

    • Although research is limited, existing research suggests that physical therapy can improve sensory awareness and motor control – and help patients identify, activate and strengthen stabilizing muscles.
    • Occupational therapy can also benefit hypermobile patients through environmental modifications, activity pacing and assistive and mobility devices like splints, braces and wheelchairs.
    • Once it has been identified, though, many strategies can help decrease pain and injuries – and improve function and quality of life.

Swinging for Hope – Bunzl Raises Record Funds for Revolutionary Pediatric Brain Tumour Treatment

Retrieved on: 
Thursday, July 13, 2023

Participants enjoyed a day of golf, fundraised and increased awareness for Toronto SickKids’ advanced pediatric brain tumour research initiatives.

Key Points: 
  • Participants enjoyed a day of golf, fundraised and increased awareness for Toronto SickKids’ advanced pediatric brain tumour research initiatives.
  • Over the last two decades, Bunzl Canada and its supporters have raised over $1.75 million to fund the revolutionary work at SickKids Hospital to combat life-threatening pediatric neurosurgical conditions.
  • This revolutionary breakthrough offers a less intrusive way to deliver targeted chemotherapy to aggressive and terminal Diffuse Intrinsic Pontine Glioma (DIPG) pediatric brain tumour.
  • MRI-guided focused ultrasound technology allows doctors to bypass the blood-brain barrier and directly target aggressive tumours within the brain stem.

Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)

Retrieved on: 
Thursday, June 1, 2023

NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem.

Key Points: 
  • NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem.
  • Disease management goals are focused on prevention of attacks, as well as understanding and tracking biomarkers that could signal these attacks.
  • The strong link suggests that higher sNfL levels may be associated with more severe attacks and increased risk of residual disability.
  • Compared with placebo, UPLIZNA was shown to hinder biomarker elevation during attacks while reducing biomarker levels over time in the absence of attacks.

St. Baldrick's Foundation Launches Cancer-Free Isn't Free Campaign in Honor of June's Cancer Survivor Month

Retrieved on: 
Thursday, June 1, 2023

LOS ANGELES, June 1, 2023 /PRNewswire/ -- In recognition of National Cancer Survivor Month in June, the St. Baldrick's Foundation , the largest charity funder of childhood cancer research grants, kicks off its "Cancer-Free Isn't Free" Campaign to raise awareness about the challenges and life-threatening conditions faced by childhood cancer survivors.

Key Points: 
  • LOS ANGELES, June 1, 2023 /PRNewswire/ -- In recognition of National Cancer Survivor Month in June, the St. Baldrick's Foundation , the largest charity funder of childhood cancer research grants, kicks off its "Cancer-Free Isn't Free" Campaign to raise awareness about the challenges and life-threatening conditions faced by childhood cancer survivors.
  • Although 85% of children diagnosed with cancer will survive at least five years after diagnosis, childhood cancer survivors are at an increased risk of adverse health and quality of life outcomes.
  • Childhood cancer survivors' most common causes of death are the return of their primary cancer, another cancer, and heart and lung damage.
  • To feature a local childhood cancer survivor or survivorship studies taking place in your area, please contact Jo Anne Avelar at [email protected].

Kurve Therapeutics, Inc. Announces Development of New Intellectual Property to Target Drug Delivery in the Brain

Retrieved on: 
Wednesday, March 15, 2023

LYNNWOOD, Wash., March 15, 2023 /PRNewswire/ -- Today, Kurve Therapeutics (Kurve Tx) announced it has filed for new intellectual property on its nose-to-brain technology platform. Kurve's technology uses the neuronal pathway rather than the circulatory system, which means the drug is delivered to the extracellular space in the brain. This means there is the opportunity to move the drug once it reaches the brain. The new IP will incorporate this ability allowing for treatments throughout the brain rather than just the frontal lobe. In contrast, the circulatory system traps the drug in the blood vessels blocking the opportunity to move the drug to a desired target.

Key Points: 
  • LYNNWOOD, Wash., March 15, 2023 /PRNewswire/ -- Today, Kurve Therapeutics (Kurve Tx) announced it has filed for new intellectual property on its nose-to-brain technology platform.
  • Kurve's technology uses the neuronal pathway rather than the circulatory system, which means the drug is delivered to the extracellular space in the brain.
  • This means there is the opportunity to move the drug once it reaches the brain.
  • In contrast, the circulatory system traps the drug in the blood vessels blocking the opportunity to move the drug to a desired target.

Acroname Launches Cost-Reduced Managed USB-C Hub Optimized for Lower Power

Retrieved on: 
Thursday, December 22, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221201005003/en/
    Acroname USBHub3c Lab Edition - native USB-C / PD capable switching hub, optimized for lower cost and lower power.
  • (Photo: Business Wire)
    Today, Acroname is launching the USBHub3c Lab Edition : a software-managed USB-C hub, host switch, port manager, and power-delivery tester, based on the industry-leading USBHub3c.
  • USBHub3c Lab Edition is cost optimized for lower power, 5V-only applications.
  • The power budgeting system also allows engineers to fine tune power sourcing when connected to high-current sink devices.

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

Retrieved on: 
Monday, November 14, 2022

This is the first FDA authorized assay for SMA screening in newborns in the United States and is part of the Companys broader EONIS Platform .

Key Points: 
  • This is the first FDA authorized assay for SMA screening in newborns in the United States and is part of the Companys broader EONIS Platform .
  • This authorization is a major milestone for newborn screening in the United States.
  • Other components of the platform include the EONIS DNA Extraction kit and EONIS Analysis Software.
  • As the global leader in newborn screening, PerkinElmer offers solutions to help identify more than 50 congenital disorders.